Shares of Dechra Pharmaceuticals plc (LON:DPH) have received an average recommendation of “Buy” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is GBX 1,842.83 ($24.99).

Separately, Jefferies Group reaffirmed a “hold” rating and issued a GBX 2,221 ($30.12) target price on shares of Dechra Pharmaceuticals in a report on Wednesday.

Shares of Dechra Pharmaceuticals (DPH) opened at GBX 2,008 ($27.23) on Wednesday. The firm has a market cap of $1,880.00 and a PE ratio of 7,171.43. Dechra Pharmaceuticals has a fifty-two week low of GBX 1,391 ($18.86) and a fifty-two week high of GBX 2,272 ($30.81).

WARNING: “Dechra Pharmaceuticals plc (DPH) Receives Average Rating of “Buy” from Analysts” was first published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at

About Dechra Pharmaceuticals

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Analyst Recommendations for Dechra Pharmaceuticals (LON:DPH)

Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.